Condition: Metastatic Non-small Cell Lung Cancer · Sponsor: AstraZeneca
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Fayetteville, Arkansas, United States | Recruiting |
| Research Site | Duarte, California, United States | Withdrawn |
| Research Site | Fountain Valley, California, United States | Recruiting |
| Research Site | La Jolla, California, United States | Recruiting |
| Research Site | Los Angeles, California, United States | Withdrawn |
| Research Site | San Diego, California, United States | Recruiting |
| Research Site | Colorado Springs, Colorado, United States | Recruiting |
| Research Site | Fort Collins, Colorado, United States | Recruiting |
| Research Site | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Research Site | Gainesville, Florida, United States | Withdrawn |
| Research Site | Jacksonville, Florida, United States | Recruiting |
| Research Site | Athens, Georgia, United States | Recruiting |
+ 291 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06417814